Search

Your search keyword '"Zhang, Yuan-Yuan"' showing total 14 results
Start Over Author "Zhang, Yuan-Yuan" Journal bone marrow transplantation
14 results on '"Zhang, Yuan-Yuan"'

1. Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience

Author

Ma, Rui, primary, Zhu, Dan-Ping, additional, Zhang, Xiao-Hui, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Mo, Xiao-Dong, additional, Lv, Meng, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Yan, Chen-Hua, additional, Chen, Yu-Hong, additional, Chen, Yao, additional, Wang, Jing-Zhi, additional, Wang, Feng-Rong, additional, Han, Ting-Ting, additional, Kong, Jun, additional, Wang, Zhi-Dong, additional, Han, Wei, additional, Chen, Huan, additional, Chang, Ying-Jun, additional, He, Yun, additional, Xu, Zheng-Li, additional, Zheng, Feng-Mei, additional, Fu, Hai-Xia, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Sun, Yu-Qian, additional

Published
2024
Full Text
View/download PDF

2. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Author

Huang, Qiu-Sha, primary, Han, Tian-Xiao, additional, Chen, Qi, additional, Wu, Jin, additional, Zhao, Peng, additional, Wu, Ye-Jun, additional, He, Yun, additional, Zhu, Xiao-Lu, additional, Fu, Hai-Xia, additional, Wang, Feng-Rong, additional, Zhang, Yuan-Yuan, additional, Mo, Xiao-Dong, additional, Han, Wei, additional, Yan, Chen-Hua, additional, Wang, Jing-Zhi, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Ting-Ting, additional, Lv, Meng, additional, Chen, Yao, additional, Wang, Yu, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2023
Full Text
View/download PDF

3. Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation

Author

Xu, Zheng-Li, primary, Xu, Lan-Ping, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Mo, Xiao-Dong, additional, Han, Ting-Ting, additional, Wang, Feng-Rong, additional, Yan, Chen-Hua, additional, Sun, Yu-Qian, additional, Chen, Yu-Hong, additional, Tang, Fei-Fei, additional, Han, Wei, additional, Wang, Yu, additional, Zhang, Xiao-Hui, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2023
Full Text
View/download PDF

4. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation

Author

Kong, Jun, primary, Zheng, Feng-Mei, additional, Wang, Zhi-Dong, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Fu, Hai-Xia, additional, Lv, Meng, additional, Chen, Huan, additional, Xu, Lan-Ping, additional, Zhang, Xiao-Hui, additional, Huang, Xiao-Jun, additional, and Wang, Yu, additional

Published
2023
Full Text
View/download PDF

5. The lower relapse rate and better survival advantages of haploidentical allograft compared with HLA-matched sibling donor allografts for intermediate- and adverse-risk AML patients with pretransplantation minimal residual disease

Author

Wang, Ming, primary, Wang, Bixia, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Zhang, Xiao-Hui, additional, Cheng, Yi-fei, additional, Sun, Yu-Qian, additional, Zhang, Yuan-Yuan, additional, Liu, Yan-Rong, additional, Chang, Ying-Jun, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2022
Full Text
View/download PDF

6. Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia

Author

Xu, Lan-Ping, primary, Xu, Zheng-Li, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Mo, Xiao-Dong, additional, Han, Ting-Ting, additional, Wang, Feng-Rong, additional, Yan, Chen-Hua, additional, Sun, Yu-Qian, additional, Chen, Yu-Hong, additional, Tang, Fei-Fei, additional, Han, Wei, additional, Wang, Yu, additional, Zhang, Xiao-Hui, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2022
Full Text
View/download PDF

7. Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation

Author

Cai, Xuan, primary, Fu, Hai-Xia, additional, Mo, Xiao-Dong, additional, Wang, Yu, additional, Zhang, Yuan-Yuan, additional, Wu, Jin, additional, Han, Wei, additional, Tang, Fei-Fei, additional, Gui, Ruo-Yun, additional, Chen, Huan, additional, Chen, Yao, additional, Zhao, Peng, additional, Yan, Chen-Hua, additional, Wang, Jing-Zhi, additional, Chen, Yu-Hong, additional, Chang, Ying-Jun, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2020
Full Text
View/download PDF

8. Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia

Author

Ma, Yan-Ru, primary, Wang, Wen-Jing, additional, Cheng, Yi-Fei, additional, Zhang, Yuan-Yuan, additional, Mo, Xiao-Dong, additional, Han, Ting-Ting, additional, Wang, Feng-Rong, additional, Yan, Chen-Hua, additional, Sun, Yu-Qian, additional, Chen, Yu-Hong, additional, Wang, Jing-Zhi, additional, Tang, Fei-Fei, additional, Han, Wei, additional, Wang, Yu, additional, Zhang, Xiao-Hui, additional, Huang, Xiao-Jun, additional, and Xu, Lan-Ping, additional

Published
2020
Full Text
View/download PDF

9. Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation

Author

Xu, Zheng-Li, primary, Xu, Lan-Ping, additional, Zhang, Yuan-Yuan, additional, Cheng, Yi-Fei, additional, Mo, Xiao-Dong, additional, Wang, Feng-Rong, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Yan, Chen-Hua, additional, Sun, Yu-Qian, additional, Han, Ting-Ting, additional, Wang, Yu, additional, Zhang, Xiao-Hui, additional, and Huang, Xiao-Jun, additional

Published
2019
Full Text
View/download PDF

10. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients

Author

Zhang, Yuan-Yuan, primary, Mo, Xiao-Dong, additional, Zhang, Xiao-Hui, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Yan, Chen-Hua, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Sun, Yu-Qian, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2019
Full Text
View/download PDF

12. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes

Author

Chen, Qi, Zhao, Xin, Fu, Hai-Xia, Chen, Yu-Hong, Zhang, Yuan-Yuan, Wang, Jing-Zhi, Wang, Yu, Wang, Feng-Rong, Mo, Xiao-Dong, Han, Wei, Chen, Huan, Chang, Ying-Jun, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a gradually recognised neurological complication of allogenic haematopoietic stem cell transplantation (allo-HSCT). However, there is a paucity of information on PRES after haploidentical HSCT (haplo-HSCT). We performed a retrospective nested case-control study in patients following haplo-HSCT for malignant and nonmalignant haematologic diseases between January 2009 and December 2018 in our centre. A total of 45 patients were diagnosed with PRES after transplant, accounting for an incidence of 1.17%. Grades II to IV acute graft-versus-host disease (aGVHD) (HR 2.370, 95% CI 1.277–4.397, p= 0.006) and hypertension (HR 14.466, 95% CI 7.107–29.443, p< 0.001) were identified as risk factors for developing PRES after haplo-HSCT. There was no difference in overall survival (OS), disease-free survival (DFS), the cumulative incidence of relapse or nonrelapse mortality (NRM) between patients with PRES and controls without PRES following haplo-HSCT in either adults or children. All but one patient with PRES showed nearly complete clinical and neurologic recovery. In conclusion, PRES is a rare condition with benign outcomes following haplo-HSCT. Further multicentre prospective studies are needed to confirm the results and help to establish the standard therapy for posttransplant PRES.

Published
2020
Full Text
View/download PDF

13. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Author

Huang QS, Han TX, Chen Q, Wu J, Zhao P, Wu YJ, He Y, Zhu XL, Fu HX, Wang FR, Zhang YY, Mo XD, Han W, Yan CH, Wang JZ, Chen H, Chen YH, Han TT, Lv M, Chen Y, Wang Y, Xu LP, Liu KY, Huang XJ, and Zhang XH

Subjects
Humans, Prognosis, Retrospective Studies, Risk Factors, Bronchiolitis Obliterans therapy, Bronchiolitis Obliterans Syndrome, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating noninfectious pulmonary complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, predictive tools for BOS are not available. We aimed to identify the clinical risk factors and establish a prognostic model for BOS in patients who undergo allo-HSCT. We retrospectively identified a cohort comprising 195 BOS patients from 6100 consecutive patients who were allografted between 2008 and 2022. The entire cohort was divided into a derivation cohort and a validation cohort based on the time of transplantation. Via multivariable Cox regression methods, declining forced expiratory volume at 1 s (FEV1) to <40%, pneumonia, cGVHD except lung, and respiratory failure were found to be independent risk factors for the 3-year mortality of BOS. A risk score called FACT was constructed based on the regression coefficients. The FACT model had an AUC of 0.863 (95% CI: 0.797-0.928) in internal validation and 0.749 (95% CI: 0.621-0.876) in external validation. The calibration curves showed good agreement between the FACT-predicted probabilities and actual observations. The FACT risk score will help to identify patients at high risk and facilitate future research on developing novel, effective interventions to personalize treatment., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2024
Full Text
View/download PDF

14. The lower relapse rate and better survival advantages of haploidentical allograft compared with HLA-matched sibling donor allografts for intermediate- and adverse-risk AML patients with pretransplantation minimal residual disease.

Author

Wang M, Wang B, Xu LP, Wang Y, Zhang XH, Cheng YF, Sun YQ, Zhang YY, Liu YR, Chang YJ, Liu KY, and Huang XJ

Subjects
Humans, Neoplasm, Residual, Siblings, Neoplasm Recurrence, Local, Allografts transplantation, Retrospective Studies, Disease-Free Survival, Survival Rate, Leukemia, Myeloid, Acute therapy, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results